Little is known about potential health risks
Product offers first combination of SGLT2 inhibitor and metformin
Cell-based vaccine is successor to trivalent Flucelvax
If approved, the product would be marketed by Merck
Combination product consists of Tresiba and Victoza
Entresto and Corlanor added to list of treatments
National Eye Institute report identifies trends by race, ethnicity, and gender
Decellularized vascular grafts will be studied in dialysis patients with ESRD

P&T May 2016
Table of Contents


Editor’s Memo
Although the death rate from cancer has fallen in recent years, progress against these diseases is uneven. This issue focuses on research efforts to find treatments.
The Obama administration has announced a drive to cure cancer, although the mission has been under way for decades. How are researchers doing, and what is in store?


Medication Errors
We must ensure safer use of oral chemotherapy
Prescription: Washington
CMS stands pat on exchange formulary standards
Approvals, new indications, regulatory activities, and more
Coagulation factor IX (recombinant), albumin fusion protein (Idelvion) for hemophilia B; captisol-enabled melphalan hydrochloride (Evomela) for multiple myeloma; and antihemophilic factor (recombinant) (Kovaltry) for hemophilia A
Meeting Highlights
Key sessions at HemOnc Today covered systemic and locoregional use of immunotherapies. At the cardiology meeting, preventive strategies took center stage.